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Abstract: 
Background and  Aims: Biliary tract cancer (BTC) is a heterogeneous group of 
malignancies with poor prognosis arising from the epithelial cells of biliary tree. Recently it 
has been reported that specific molecular mutations are associated with different types of 
biliary tree carcinomas, supporting their pathologic and molecular heterogeneity. However, 
the pathogenic pathways involved in carcinogenesis of BTC are still to be fully defined, and 
data regarding the relationship between molecular alterations and pattern or timing of 
recurrence is lacking. The aim of the present study was to investigate the relationship between 
the mutational gene profile and the pattern of recurrence in BTCs. 
Patients and Methods: From September 1990 to December 2012, a total of 103 specimens of 
patients with BTC (56 PCC, 35 ICC, and 12 GBC), who underwent curative surgery in a single 
tertiary HPB surgery referral center, were assessed for mutational status in 56 cancer-related 
genes. 
Results: Considering the different types of BTC, the 5-years RFS rate was 16.7%. (median 
RFS, 7 months) in GBC, 42.9%. (median RFS, 26.4 months) in ICC, 19.7% (median RFS, 16.5 
months) in PCC, p=0.166 (figure 3).  
The presence of mutations in ARID1A, BRAF, ERBB2, FGFR3, PIK3CA and TP53 genes was 
significantly associated with poor RFS compared with wild type tumors (median RFS of 11.5 
months vs. 19.2 months, p=0.039;  3.0 months vs. 17.0 months, p= 0.002;  5.0 months vs 16.5 
months, p=0.017; 5.1 months vs. 16.5 months, p=0.024; 11.1 months vs 18.5 months , p= 0.032 
and 8.6 months vs 21.9 months , p = 0.003 respectively). 
At the multivariate analysis including clinical, pathological and molecular characteristics, the 
factors independently related with survival were: Radicality of surgery (OR 2.050, C.I. 1.104-
3.807, p=0.023), LN status (OR 1.835, C.I. 1.006-3.348, p=0.048), mutational status of ARID1A 
(OR 2.566, C.I. 1.174-5.608, p=0.018) and TP53 (OR 2.805, C.I. 4.432-5.496, p=0.003). 
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Considering the pattern of recurrence, local recurrence occurred in 47 patients (73.4%) , while  
systemic recurrence occurred in 17 patients (26.4%) .  
Regarding the prognostic genes identified at the univariate analysis: ARID1A mutation was 
associated with a local and systemic recurrence in the 43% and 29% of cases, respectively; 
BRAF mutation was associated with a local and systemic recurrence in the 33% and 33% of 
cases, respectively; ERBB2 and FGFR3  mutation were always associated  with a local 
recurrence; PIK3CA mutation was related with a local and systemic recurrence in the 72% and 
14% of cases, respectively; and TP53 mutation was associated with a local and systemic 
recurrence in the 29% and 41% of cases. Regarding other genes with relatively high rate of 
mutation: BAP1 mutation was associated with a local and systemic recurrence in the 57% and 
29% of cases, respectively; KRAS mutation was related with a local and systemic recurrence 
in the 42% and 10% of cases, respectively; PBRM1 mutation was associated in the 64% of 
cases  with a local recurrence.  
Conclusion:  
Our study reported specific prognostic genes for GBC, PCC and ICC that can identify patients 
with poor prognosis after curative surgery . Moreover,  we analyzed the relationship between 
the mutational gene profile and the recurrence of BTCs. Disease-specific genes identified can 
be explored for new molecular therapies in clinical trial.  
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Introduction: 
Biliary tract cancer (BTC) is a heterogeneous group of malignancies with poor 
prognosis arising from the epithelial cells of biliary tree 1,2. They represent the second most 
common type of hepatobiliary cancer worldwide accounting for approximately 3% of all 
gastrointestinal malignancies 3 . 
 BTC are classified according to their site of origin: gallbladder cancer (GBC), 
intrahepatic cholangiocarcinoma (ICC) arising from intrahepatic bile ducts, perihilar 
cholangiocarcinoma (PCC) arising or involving the hepatic biliary confluence, and distal 
cholangiocarcinoma (DCC) arising from the bile duct distal to the cystic duct origin 4,5. 
Regardless of its location BTCs are very aggressive diseases with high rate of local diffusion 
and metastatic spreading. 
 The global epidemiological trends in incidence of BTC vary according to geographic 
regions. Several conditions are considered risk factors for development of BTC such as chronic 
cholangitis 6,7, liver fluke infection 7,8 viral hepatitis 7,.8,  aflatoxin exposure 9 or other chemical 
exposure 7,10. Gallbladder cancer is more common in females, while intrahepatic and peri-hilar 
cholangiocarcinoma have a male predominance 11. As a general rule, the incidence of BTC 
increases with age; the typical patient with these malignancies is between 60 and 70 years old. 
However, BTC arising in the setting of primary sclerosing cholangitis (PSC) and those with 
choledochal cysts occur in nearly two decades younger patients 12,13.  
 Surgical resection is the only treatment offering chance of long-term survival, but 
most cases are unresectable at the time of the diagnosis 14,15. However, curative resection is 
possible in less than one-half of patients, and the majority does not achieve long-term disease 
control 16-21  . Resectability rates for BTC have increased over time, due to more aggressive 
operative strategies and extended criteria for resectability. The goal for surgical treatment of 
BTC is to achieve a radical resection with negative histologic margin (R0 resection). In 
literature, the rate of R0 resection varies according to the type of BTC from 70% to 90%. 22-29 
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Nevertheless, even in case of complete radical resection, the majority of BTC recur either 
locally  or with distant metastases 30-31. Recurrence is a specific prognostic parameter that 
reflects the biological aggressiveness of these tumors.  
 The standard treatment for advanced unresectable cholangiocarcinoma are cisplatin or 
gemcitabine based chemotherapy regimen, but the response rate to these chemotherapy is low, 
consequently even in treated patients the prognosis is poor with only 5-10% five-year overall 
survival rate 32. Nowadays, no effective molecular targeted agent has been approved for biliary 
tract cancers outside of clinical trial. 
 Recently it has been shown that specific molecular mutations are associated with 
different types of biliary tree carcinomas, supporting their pathologic and molecular 
heterogeneity. 
 A retrospective study 33 identified molecular subgroups of cholangiocarcinomas that can 
be explored for specific drug targeting in clinical trials. In that study the mutational status of 56 
cancer-related genes in 153 biliary tract cancers was assayed. The genes most frequently 
involved were KRAS (28%), TP53 (18%), ARID1A (12%), IDH1/2 (9%), PBRM1 (9%), BAP1 
(7%), and PIK3CA (7%). In particular IDH1/2 (p=0.0005) and BAP1 (p=0.0097) mutations 
were characteristic of ICC, while KRAS (p=0.0019) and TP53 (p=0.0019) were more frequent 
in ECC and GBC. Furthermore TP53 was identify as an independent prognostic factor in 
cholangiocarcinoma.  
 In a previous study 34 we reported specific prognostic genes in terms of overall survival 
that can identify patients with poor prognosis after curative surgery. In particular  91 patients 
with cholangiocarcinoma who underwent curative surgery were assessed for mutational status 
in 56 cancer-related genes.  ALK and IDH1 mutation had an exclusive prognostic impact for 
PCC, and ARID1A, PIK3C2G, STK11, and TGFBR2 for ICC. However, mutation of TP53 
confirmed as a negative molecular prognostic factor. In fact the presence of mutations in ALK, 
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IDH1, and TP53 genes was significantly associated with poor prognosis in patients with PCC 
compared to wild type (median overall survival 5.0 vs. 34.9 months, p=0.001, 9.1 vs. 29.6 
months, p = 0.043; and 15.4 vs. 32.5 months, p = 0.019, respectively). On the other hand 
mutations of ARID1A, PIK3C2G, STK11, TGFBR2, and TP53 genes was significantly 
associated with poor prognosis in patients with ICC compared to wild type (median overall 
survival of 14.0 vs.52.0 months, p = 0.012; 11.8 vs. 40.1 months, p = 0.030; 11.8 vs. 40.1 
months, p = 0.030; 9.3 vs. 40.1 months, p = 0.011; and 5.7 vs. 40.1 months, p = 0.011, 
respectively).  
 Wardell C et al  35 performed a large-scale genome sequencing analysis of 412 BTC 
samples from Japanese and Italian series (136 ICC, 101 DCC, 109 PCC, and 66 GBC) to 
investigate their somatic and germline driver events and characterize their genomic landscape. 
They identified 32 significantly and commonly mutated genes including TP53, KRAS, 
SMAD4, NF1, ARID1A, PBRM1, and ATR, suggesting that KRAS, MUC17 and ARID1A 
negatively affected patient prognosis. Moreover, the authors identified somatic alterations and 
searched for driver genes in BTCs, finding pathogenic germline variants of cancer-
predisposing genes predicting cell-of-origin for BTCs by combining somatic mutation 
patterns and epigenetic features. 
 There is evidence that ICC is more frequently due to alterations in genes involved in 
epigenetic regulation 33,36 whereas extrahepatic and gallbladder subtypes are driven by 
mutations in TP53 and cell cycle genes. However, the pathogenic pathways involved in 
carcinogenesis of BTC are still to be fully defined, and data regarding the relationship between 
molecular alterations and pattern or timing of recurrence is lacking. 
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The aim of the present study was to investigate the relationship between the mutational gene 
profile and the pattern of recurrence in BTCs. 
 
 
 
Patients and Methods: 
Ethics statement 
Data collection and analysis were performed according to the institutional guidelines and 
conformed to the ethical standards of the World Medical Association (Declaration of Helsinki).	
Specimens of resected patients were retrospectively retrieved from the formalin fixed paraffin 
embedded (FFPE) archives of the Department of Pathology-Diagnostics and the Arc-Net 
biobank of the University and Hospital Trust of Verona under a local ethics committee ARC-
Net approval number prog. 1959. 
 
Definition of Biliary Tract Cancers subtypes 
Biliary Tract Cancer (BTC) were classified according to WHO 2010 and AJCC/UICC 7th 
edition criteria as gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (ICC) and 
perihilar cholangiocarcinoma (PCC) 3,4.  
Patients 
From September 1990 to December 2012, a total of 194 patients with BTC submitted to surgical 
resection with radical intent in a single tertiary HPB surgery referral centre. In 103 BTC 
specimens the material was sufficient for the pathological and molecular analysis. 
The clinical and pathological data were prospectively collected in all patients. For the 103 BTC, 
tissue microarrays (TMAs) were also prepared using two 1-mm cores for each case.  
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DNA extraction and PCR Amplifications 
As previously described 33,34 DNA was prepared from tissues after enrichment for neoplastic 
cellularity using manual microdissection. A total of 5 to 15 consecutive 4-µm FFPE sections 
per case were used. DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen). 
Purified DNA was quantified and its quality assessed using NanoDrop (Invitrogen Life 
Technologies) and Qubit (Invitrogen Life Technologies) platforms 38. DNA quality was further 
evaluated by PCR analysis using the BIOMED 2 PCR multiplex protocol 39 with PCR products 
analyzed by DNA 1000 Assay (Invitrogen Life Technologies) on the Agilent 2100 Bioanalyzer 
on-chip electrophoresis (Agilent Technologies). 
Two multigene panels were used: the 50-gene Ion AmpliSeq Cancer Hotspot Panel v2 (Life 
Technologies) and a 7-gene AmpliSeq Custom Panel. The first explores selected regions of the 
following 50 cancer-associated genes, in alphabetical order: ABL1, AKT1, ALK, APC, ATM, 
BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, 
FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, 
KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, 
PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. The details 
of the target regions may be found at http://www.lifetechnologies.com. The 7-gene custom 
panel was designed to target selected regions of a gene included in the 50-gene panel (IDH2) 
and six genes that were selected according to the results of a previously published ICC exome 
sequencing study (ARID1A, BAP1, PBRM1, PIK3C2A, PIK3C2G, TGFBR2)40.  
Sequencing was run on the Ion Torrent Personal Genome Machine (PGM, Life Technologies) 
loaded with 316 (50-gene panel) or 318 chips (7-gene panel).  
 
Statistical analysis 
  
8 
Data were collected and analyzed with SPSS statistical software (SPSS version 21 Inc. Chicago 
Ill.) The differences between categorical variables were analyzed with a chi-square test. 
Comparisons between means were carried out with a t test. Recurrence Free Survival analysis 
was carried out using the Kaplan-Meier method. We considered the treatment day as time zero 
and patients recurrence free at the end of follow-up were considered censored. The mean 
follow-up period was 42.6 ± 36.2 months. Ten patients with 90-days postoperative mortality (1 
GBC, 1 ICC and 8 PCC) were excluded from survival analysis. 
A multivariate analysis including the clinical, pathological and molecular factors related to 
survival at the univariate analysis (with a p value < 0.05) were carried out with Cox’s regression 
model with forward and backward analysis to identify factors that were independently related 
with survival. The p value < 0.05 was regarded as statistically significant. 
 
Results: 
The clinical and pathological features of the 103 patients included in the study are summarized 
in Table 1.  The median age of the patients was 66 years (IQR 60 to 72) .  The study population 
included 12 Gallbladder Cancer (GBC), 35 Intrahepatic Cholangiocarcinoma (ICC), and 56 
Perihilar Cholangiocarcinoma (PCC). Sixty-seven patients were male (65.0%) and 36 were 
female (35.0%). Major hepatectomy was required in 72 patients (69.9%). R0 resection was 
achieved in 76 patients (73.8%). Lymph node dissection was performed in 96 patients  (95.2%) 
and the rate of positive lymph-node was 46.7%. Microvascular invasion and perineural invasion 
was found in 74 patients (71.8%) and 64 (62.1%) of patients, respectively. The postoperative 
mortality was  9.7% (n 10). 
A detailed description of gene mutations in GBC, ICC and PCC is reported in Table 2 and 
Figure 1. No mutations were identified in the following 19 genes: ABL1, AKT1, ATM, CDH1, 
CSF1R, FGFR1, FGFR2, FLT3, HNF1A, JAK2, JAK3, MET, MPL, NOTCH1, NPM1, 
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PDGFRA, RB1, RET, SMO and SRC. At least one gene mutation was identified in 77.7 % of 
the tumors (n=80). 51% of the tumors reported more than one gene mutation (n=41). 
The most frequently mutated genes in  GBC was TP53, with mutation in  41.7% (n 5) of the 
tumors.  Other genes with a high rate of mutations (over 10%) in GBC  were: KRAS in 25.0% 
(n 3), ARID1A in 16.7% (n 2) and SMAD4 in 16.7% (n 2). 
In  ICC  the most frequently mutated genes were NRAS and IDH1 with mutation in 17.1% (n 
6) of the tumors. Other genes with a rate of mutations over 10% in ICC were: BAP1 in 14.3% 
(n 5), ARID1A in 11.4% (n 4) and PBRM1 in 11.4% (n 4).  
The most frequently mutated gene in PCC was KRAS, with mutation in 41.1% (n 23) of the 
tumors. Other genes with a high rate of mutations (over 10%) in PCC were: TP53 in 19.6% (n 
11), ARID1A in 14.3% (n 8) and PBRM1 in 10.7% (n 6).  
 
Comparison in molecular profile between GBC, ICC and PCC 
The results of the univariate analysis of comparison in molecular profile among the three groups 
are showed in table 2. 
We observed a statistically significant higher frequency of mutation for KRAS, in PCC and 
GBC compared with ICC, in 41.1%, 25.0% and 8.6% of tumors, respectively, p=0.003. 
Moreover, TP53 resulted most commonly mutated in PCC and GBC compared with ICC, in 
19.6%, 41.7% and 5.7% of tumors, respectively, p=0.015. Conversely, IDH1 and BAP1 were 
more commonly mutated in ICC compared with GBC and PCC, in particular IDH1 was mutated 
in 17.1% (n 6), 0% and 3.6% (n 2) of tumors, respectively, p = 0.035, and BAP1 was mutated 
in 14.3% (n 5), 0% and 3.6% (n 2) of tumors, respectively, p = 0.087.   
APC, ERBB2, SMARCB1 and RB1 were mutated only in GBC. ERBB4, FGFR3 and NRAS 
were mutated only in ICC. ALK, CTNNB1, FBXW7, GNAS, KIT and PTPN11 were mutated 
only in PCC. 
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Relationship between gene mutations and clinic-pathological characteristics  
The relationship between gene mutation and clinic-pathological features of patients is shown 
in Figure 2.  
ARID1A had an higher frequency of mutation in patients < 70 years compared with > 70 years 
(18.5% vs 5.3 % , p=0.050). KRAS mutation resulted in  35.9 % of resected tumors with 
perineural invasion compared with 15.4 % of resected tumors without perineural invasion (p= 
0.020). PIK3CA mutation  is always associated with microvascular invasion  (p= 0.041). 
TP53 was more frequently mutated in patients with positive LN compared with patients with 
negative LN (23.9 % vs 11.5 %, p=0.039), in high grade tumors (G3-G4) compare with low 
grade tumors (G1–G2) (31% vs 12.2 %, p= 0.027) and in tumor with perineural invasion  
compare with tumor without perineural invasion (23.4% vs 7.7 %, p= 0.034). 
 
Factors related with Recurrence Free Survival (RFS) after surgery 
The results of the univariate analysis and multivariate analysis of recurrence free survival (RFS) 
in the study population are shown in Table 3.  
Considering the different types of BTC, the 5-years RFS rate was 16.7%. (median RFS, 7 
months) in GBC, 42.9%. (median RFS, 26.4 months) in ICC, 19.7% (median RFS, 16.5 months) 
in PCC, p=0.166 (figure 3). The the 5-years RFS rate was 31.0% in patients with negative 
lymph nodes (median RFS, 26.4 months) compared with 24.9% (median RFS 11.0 months) in 
patients with positive lymph nodes, p = 0.006 (figure 4). The the 5-years RFS rate was 33.4% 
in R0 resection (median RFS, 30.5 months) compared with 5.9% (median RFS 17.1 months) in 
patients with positive margin (R1), p = 0.002 (figure 5). The the 5-years RFS rate was 38.5% 
in patients without microvascular invasion (median RFS 29.5 months ) compare with 22.5% 
(median RFS 12.2 months) in patients with microvascular invasion, p = 0.009. Moreover, The 
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the 5-years RFS rate was 32.2% in patients with AJCC Stage I-II tumors (median RFS 26.4 
months ) compare with 23.4% (median RFS 12.0 months) in patients with AJCC Stage III-IV 
tumors, p = 0.024.   
The presence of mutations in ARID1A (figure 6), BRAF, ERBB2, FGFR3, PIK3CA and TP53 
(figure 7) genes was significantly associated with poor RFS compared with wild type tumors 
(median RFS of 11.5 months vs. 19.2 months, p=0.039;  3.0 months vs. 17.0 months, p= 0.002;  
5.0 months vs 16.5 months, p=0.017; 5.1 months vs. 16.5 months, p=0.024; 11.1 months vs 
18.5 months , p= 0.032 and 8.6 months vs 21.9 months , p = 0.003 respectively) (see table 3). 
At the multivariate analysis including clinical, pathological and molecular characteristics, the 
factors independently related with survival were: Radicality of surgery (OR 2.050, C.I. 1.104-
3.807, p=0.023), LN status (OR 1.835, C.I. 1.006-3.348, p=0.048), mutational status of ARID1A 
(OR 2.566, C.I. 1.174-5.608, p=0.018) and TP53 (OR 2.805, C.I. 4.432-5.496, p=0.003). 
 
Timing and pattern of recurrence 
Recurrence occurred in 63 patients (67.7%), in particular,  31 patients (49.1%) recurred within 
12 months from surgery (early recurrence), the trend of frequency of recurrence according with 
time after surgery is show in figure 8. In early recurrence group the frequency of mutation of 
BRAF, PIK3CA and TP53  were higher compared with other patients (13.3% vs 0%, p =0.027, 
15.2% vs 1.8%, p=0.025 and 27.3% vs 10.7%, p=0.044, respectively). 
Moreover BAP1 mutation was related with late recurrence (> 24 months after surgery), 
p=0.046. 
Considering the pattern of recurrence, local recurrence occurred in 47 patients (73.4%) , while  
systemic recurrence occurred in 17 patients (26.4%) .  
We observed a relationship between  the pattern of recurrence and the mutational gene profile 
(Figure 9 and Figure 10). Regarding the prognostic genes identified at the univariate analysis: 
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ARID1A mutation was associated with a local and systemic recurrence in the 43% and 29% of 
cases, respectively; BRAF mutation was associated with a local and systemic recurrence in the 
33% and 33% of cases, respectively; ERBB2 and FGFR3  mutation were always associated  
with a local recurrence; PIK3CA mutation was related with a local and systemic recurrence in 
the 72% and 14% of cases, respectively; and TP53 mutation was associated with a local and 
systemic recurrence in the 29% and 41% of cases. Regarding other genes with relatively high 
rate of mutation: BAP1 mutation was associated with a local and systemic recurrence in the 
57% and 29% of cases, respectively; KRAS mutation was related with a local and systemic 
recurrence in the 42% and 10% of cases, respectively; PBRM1 mutation was associated in the 
64% of cases  with a local recurrence.  
 
 
 
Discussion 
 
Biliary tract cancers (BTCs) are clinically and pathologically heterogeneous malignancies 
with poor response to treatments .Surgical resection is the only potential cure for BTC . 
Although resectability has improved recently, the success rate remains poor and  even in case 
of complete radical resection, the majority of BTC recurred.	In	our	study		the 67.7% of 
resected tumors recurred even if the R0 resection was achieved in  76 patients (73.8%). This 
is probably related to different  mutational profile that influence the aggressive behaviour  of 
these tumors. 
Genomic profiling can offer a clearer understanding of their carcinogenesis, classification and 
treatment strategy.  
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In this study, we analyzed the molecular features of GBC, PCC and ICC of a series from a 
single tertiary HPB referral center and confirmed previously published data33,34 . The main 
findings of our study showed: specific molecular characteristics for GBC, PCC and ICC  and 
distinctive molecular prognostic factors for GBC, PCC and ICC. 
From our data, the macroscopic type of GBC, PCC and ICC seem to have significant differences 
at the molecular level.  
The most frequently mutated genes in  GBC were TP53(41.7% ), KRAS ( 25.0%), ARID1A 
(16.7%) and SMAD4 (16.7). In  ICC  the most frequently mutated genes were NRAS (17.1%), 
IDH1( 17.1%) , BAP1 (14.3%) , ARID1A (11.4%) and PBRM1 (11.4%) The most frequently 
mutated gene in PCC were KRAS( 41.1%) ,TP53 (19.6%) , ARID1A ( 14.3%) and PBRM1 
(10.7%).  
Moreover, our study confirmed that some gene mutations are specific for the different subtypes 
of BTC : APC, ERBB2, SMARCB1 and RB1 were mutated only in GBC, ERBB4, FGFR3 and 
NRAS were mutated only in ICC, ALK, CTNNB1, FBXW7, GNAS, KIT and PTPN11 were 
mutated only in PCC. 
We observed a relationship between specific gene mutations and the clinic-pathological 
characteristics of the tumors. In particular ARID1A had an higher frequency of mutation in 
patients < 70 years old , KRAS in tumors  with perineural invasion , PIK3CA in tumors with 
microvascular invasion  . On the other hand TP53 was more frequently mutated in patients with 
positive LN ,  high grade tumors (G3-G4) and in tumor with perineural invasion .  
Analyzing the mutational profile and the clinic-pathological features of the patients  in relation 
with the recurrence free survival rate, we found clinical and molecular independent prognostic 
factors. Our data confirmed that the surgical radicality , the LN status , the mutational status of 
ARID1A and TP53  represent prognostic factor independently related with survival. Other gene 
significantly associated with poor RFS were BRAF, ERBB2, FGFR3 and PIK3CA. 
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Moreover we observed a relationship between specific gene mutation and the timing of 
recurrence. In particular, BRAF, PIK3CA and TP53 mutation was associated to early recurrence 
(within 12months), while mutation of BAP1 was associated with late recurrence (after 12 
months ). 
Furthermore we assessed a relationship between  the pattern of recurrence and the mutations of  
the prognostic genes. Considering the mutations of the genes independently related whit a poor 
prognosis , we found that ARID1A mutation was more frequently associated  with a local 
recurrence while TP53 mutation was more frequently associated  with a systemic recurrence;  
A limitation of the current study is the small sample size, although data in the literature on the 
molecular profiling of BTCs are frequently multi-institutional and limited to a small number of 
patients. Moreover, statistical analysis on differences between subgroups and survival analysis 
could be suboptimal due to the low frequency rate of some gene mutations.  
An external validation and further study are needed to confirm our results. 
 
 
Conclusions 
Mutational genes profiling identified different gene mutations between GBC, PCC and ICC. In 
particular, our study reported specific prognostic genes for GBC, PCC and ICC that can identify 
patients with poor prognosis after curative surgery . Moreover,  we analyzed the relationship 
between the mutational gene profile and the recurrence of BTCs. Disease-specific genes 
identified can be explored for new molecular therapies in clinical trial.  
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Tables and Figures 
Table 1. Clinical and pathological features of 103 patients included in the study 
 BTC 
 (n=103) 
Age, year, median (IQR) 66 (60-72) 
Gender, M/F (%) 67 (65.0) / 36 (35.0) 
Gallbladder Cancer, n (%) 
Intrahepatic Cholangiocarcinoma, n (%) 
Peri-hilar Cholangiocarcinoma, n (%) 
12 (11.7) 
35 (34.0) 
56 (54.4) 
Major Hepatectomy, n (%) 72 (69.9) 
Bile Duct Resection, n (%) 56 (54.4) 
Portal Vein Resecion, n (%) 15 (14.6) 
Hepatic Artery Resection, n (%) 2 (1.9) 
Postoperative Mortality, n (%) 10 (9.7) 
R0 Resection, n (%) 76 (73.8) 
Lymphnode Status, n (%)  N/A 7 (6.8) 
 Negative 50 (48.5) 
 Positive 46 (46.7) 
Histologic Grading, n (%) G1-2 
G3-4 
74 (71.8) 
29 (28.2) 
Perineural Invasion, n (%)  64 (62.1) 
Microvascular Invasion, n (%)  74 (71.8) 
AJCC Stage, n (%)  I 10 (9.7) 
 II 29 (28.2) 
 III 43 (41.7) 
 IV 19 (18.4) 
 N/A 2 
BTC, Biliary Tract Cancer; AJCC, American Joint Committee on Cancer Staging System;  
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Table 2. Frequency and comparison of gene mutations in the study population, including 12 
Gallbladder Cancer (GBC), 35 Intrahepatic Cholangiocarcinoma (ICC), and 56 Perihilar 
Cholangiocarcinoma (PCC).  
Gene 
mutations 
TOT 
n 103 
GBC 
n 12 
ICC 
n 35 
PCC 
n 56 
p values 
ALK 
APC 
1 (0.9%) 
1 (0.9%) 
0 
1 (8.3%) 
0 
0 
1 (1.8%) 
0 
0.655 
0.112 
ARID1A 14 (13.6%) 2 (16.7%) 4 (11.4%) 8 (14.3%) 0.879 
BAP1 7 (6.8%) 0 5 (14.3%) 2 (3.6%) 0.087 
BRAF 3 (2.9%) 0 2 (5.7%) 1 (1.8%) 0.453 
CDKN2A 2 (1.9%) 1 (8.3%) 0 1 (1.8%) 0.194 
CTNNB1 1 (0.9%) 0 0 1 (1.8%) 0.655 
EGFR 
ERBB2 
2 (1.9%) 
1 (0.9%) 
1 (8.3%) 
1 (8.3%) 
0 
0 
1 (1.8%) 
0 
0.194 
0.022 
ERBB4 1 (0.9%) 0 1 (2.9%) 0 0.375 
FBXW7 2 (2.9%) 0 0 2 (3.6%) 0.425 
FGFR3 1 (0.9%) 0 1 (2.9%) 0 0.375 
GNAS 1 (0.9%) 0 0 1 (1.8%) 0.655 
HRAS 1 (0.9%) 0 0 1 (1.8% 0.655 
IDH1 8 (7.7%) 0 6 (17.1%) 2 (3.6%) 0.035 
IDH2 2 (1.9%) 0 1 (2.9%) 1 (1.8%) 0.819 
KDR 3 (2.9%) 1 (8.3%) 0 2 (3.6%) 0.304 
KIT 1 (0.9%) 0 0 1 (1.8%) 0.655 
KRAS 29 (28.1%) 3 (25.0%) 3 (8.6%) 23 (41.1%) 0.003 
MLH1 1 (0.9%) 0 0 1 (1.8%) 0.655 
NRAS 6 (5.8%) 0 6 (17.1%) 0 0.002 
PBRM1 11 (10.7%) 1 (8.3%) 4 (11.4%) 6 (10.7%) 0.956 
PIK3CA 7 (6.8%) 1 (8.3%) 1 (2.9%) 5 (8.9%) 0.321 
PIK3C2A 4 (3.9%) 0 1 (2.8%) 3 (5.4%) 0.635 
PIK3C2G 6 (5.8%) 0 1 (2.8%) 5 (8.9%) 0.319 
PTEN 4 (3.9%) 1 (8.3%) 1 (2.8%) 2 (3.6%) 0.687 
PTPN11 1 (0.9%) 0 0 1 (1.8%) 0.655 
SMAD4 
SMARCB1 
5 (4.8%) 
1 (0.9%) 
2 (16.7%) 
1 (8.3%) 
0 
0 
2 (3.6%) 
0 
0.066 
0.022 
STK11 
RB1 
2 (1.9%) 
1 (0.9%) 
0 
1 (8.3%) 
1 (2.8%) 
0 
1 (1.8%) 
0 
0.819 
0.022 
TGFBR2 5 (4.8%) 1 (8.3%) 1 (2.8%) 3 (5.4%) 0.723 
TP53 18 (17.5%) 5 (41.7%) 2 (5.7%) 11 (19.6%) 0.015 
 
 
Table 3. Univariate and multivariate analysis of recurrence free survival in the study 
population. 
 Univariate Analysis Multivariate analysis 
 Median survival 
(months) 
5-years RFS rate 
(%) 
p values Hazard Ratio  95% C.I. p values 
Age, year < 70 16.0 22.1 0.316    
 ≥ 70 24.5 37.0     
Gender M 15.0 28.4 0.818    
 F 19.2 26.3     
Gallbladder Cancer 
Intrahepatic Cholangiocarcinoma 
Peri-hilar Cholangiocarcinoma 
7.0 
26.4 
16.5 
16.7 
42.9 
19.7 
0.166 
  
 
Radicality R0 21.9 33.4 0.002 2.050 1.104-3.807 0.023 
 R1 9.0 5.9     
Lymph-node Status Negative 26.4 31.0 0.006 1.835 1.006-3.348 0.048 
 Positive 11.0 24.9     
Grading  G1-G2 18.5 28.5 0.586    
 G3-G4 12.0 23.8     
Microvascular 
Invasion 
0 29.5 38.5 0.009    
 1 12.2 22.5     
Perineural Invasion 0 26.7 28.2 0.340    
 1 14.7 27.0     
AJCC-UICC Stage I-II 26.4 32.2 0.024    
 III-IV 12.0 23.4     
ARID1A wt 19.2 31.5 0.039 2.566 1.174-5.608 0.018 
 mut 11.5 0.0     
BRAF wt 17.0 27.8 0.002    
 mut 3.0 0.0     
ERBB2 wt 16.5 27.5 0.017    
 mut 5.0 0.0     
FGFR3 wt 16.5 27.5 0.024    
 mut 5.1 0.0     
PIK3CA wt 18.5 29.3 0.032    
 mut 11.0 0.0     
TP53 wt 21.9 31.2 0.003 2.805 1.432-5.496 0.003 
 mut 8.6 0.0     
 
 
Figura 1. Detailed description on gene mutations in the study population. Each column represent a patient, genes tested are listed in rows. Red 
rectangles indicate mutations in a given gene and patient 
 
Gene Mutation (n,%) Gallbladder Cancer (n12) Intrahepatic Cholangiocarcinoma (n 35) Peri-hilar Cholangiocarcinoma (n 56)
KRAS 29 (28.1%)
TP53 18 (17.5%)
ARID1A 14 (13.6%)
PBRM1 11 (10.7%)
IDH1 8 (7.7%)
BAP1 7 (6.8%)
PIK3CA 7 (6.8%)
NRAS 6 (5.8%)
PIK3C2G 6 (5.8%)
SMAD4 5 (4.8%)
TGFBR2 5 (4.8%)
PIK3C2A 4 (3.9%)
PTEN 4 (3.9%)
BRAF 3 (2.9%)
KDR 3 (2.9%)
CDKN2A 2 (1.9%)
EGFR 2 (1.9%)
FBXW7 2 (1.9%)
IDH2 2 (1.9%)
STK11 2 (1.9%)
ALK 1 (0.9%)
APC 1 (0.9%)
CTNNB1 1 (0.9%)
ERBB2 1 (0.9%)
ERBB4 1 (0.9%)
FGFR3 1 (0.9%)
GNAS 1 (0.9%)
HRAS 1 (0.9%)
KIT 1 (0.9%)
MLH1 1 (0.9%)
PTPN11 1 (0.9%)
RB1 1 (0.9%)
SMARCB1 1 (0.9%)
ABL1 0
AKT1 0
ATM 0
CDH1 0
CSF1R 0
FGFR1 0
FGFR2 0
FLT3 0
HNF1A 0
JAK2 0
JAK3 0
MET 0
MPL 0
NOTCH1 0
NPM1 0
PDGFRA 0
RET 0
SMO 0
SRC 0
  
1 
Figura 2. Relationship between gene mutation and clinical characteristics. Frequency of gene mutation in the study population are reported 
between round brake. Each column represent the frequency of specific gene mutation in the different subgroups. 
 
Figure 3. Recurrence Free Survival curves according to type of Biliary Tract Cancer (BTC): 
Intrahepatic Cholangiocarcinoma, green line; Peri-hilar Cholangiocarcinoma, red line; 
Gallbladder Cancer, blue line; p = 0.166.
 
Figure 4. Recurrence Free Survival curves according to Lymph-node (LN) status: Negative 
LN, blue line; Positive LN, green line; p = 0.006. 
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Figure 5. Recurrence Free Survival curves according to Radicality of surgery: R0 resection, 
blue line; R1 resection, green line; p = 0.002. 
 
Figure 6. Recurrence Free Survival curves according to mutational status of ARID1A: Wild 
type, blue line; Mutated, green line; p = 0.039. 
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Figure 7. Recurrence Free Survival curves according to mutational status of TP53: Wild type, 
blue line; Mutated, green line; p = 0.003. 
 
Figure 8. Frequency of recurrence during different time period after surgery and specific gene mutations. 
  
  
1 
Figure 9. Type of recurrence according to mutation of prognostic genes identified at Recurrence Free Survival univariate analysis 
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Figure 10. Type of recurrence according to mutation of other most common mutated genes. 
 
 
 
